Cargando…

Associations of [(18)F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism

Molecular imaging of tauopathies is complicated by the differing specificities and off-target binding properties of available radioligands for positron emission tomography (PET). [(18)F]-APN-1607 ([(18)F]-PM-PBB3) is a newly developed PET tracer with promising properties for tau imaging. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jiaying, Bao, Weiqi, Li, Ming, Li, Ling, Zhang, Zhengwei, Alberts, Ian, Brendel, Matthias, Cumming, Paul, Lu, Huimeng, Xiao, Zhenxu, Zuo, Chuantao, Guan, Yihui, Zhao, Qianhua, Rominger, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338611/
https://www.ncbi.nlm.nih.gov/pubmed/32694971
http://dx.doi.org/10.3389/fnins.2020.00604
_version_ 1783554718831738880
author Lu, Jiaying
Bao, Weiqi
Li, Ming
Li, Ling
Zhang, Zhengwei
Alberts, Ian
Brendel, Matthias
Cumming, Paul
Lu, Huimeng
Xiao, Zhenxu
Zuo, Chuantao
Guan, Yihui
Zhao, Qianhua
Rominger, Axel
author_facet Lu, Jiaying
Bao, Weiqi
Li, Ming
Li, Ling
Zhang, Zhengwei
Alberts, Ian
Brendel, Matthias
Cumming, Paul
Lu, Huimeng
Xiao, Zhenxu
Zuo, Chuantao
Guan, Yihui
Zhao, Qianhua
Rominger, Axel
author_sort Lu, Jiaying
collection PubMed
description Molecular imaging of tauopathies is complicated by the differing specificities and off-target binding properties of available radioligands for positron emission tomography (PET). [(18)F]-APN-1607 ([(18)F]-PM-PBB3) is a newly developed PET tracer with promising properties for tau imaging. We aimed to characterize the cerebral binding of [(18)F]-APN-1607 in Alzheimer’s disease (AD) patients compared to normal control (NC) subjects. Therefore, we obtained static late frame PET recordings with [(18)F]-APN-1607 and [(18)F]-FDG in patients with a clinical diagnosis of AD group, along with an age-matched NC group ([(18)F]-APN-1607 only). Using statistical parametric mapping (SPM) and volume of interest (VOI) analyses of the reference region normalized standardized uptake value ratio maps, we then tested for group differences and relationships between both PET biomarkers, as well as their associations with clinical general cognition. In the AD group, [(18)F]-APN-1607 binding was elevated in widespread cortical regions (P < 0.001 for VOI analysis, familywise error-corrected P < 0.01 for SPM analysis). The regional uptake in AD patients correlated negatively with Mini-Mental State Examination score (frontal lobe: R = -0.632, P = 0.004; temporal lobe: R = -0.593, P = 0.008; parietal lobe: R = -0.552, P = 0.014; insula: R = -0.650, P = 0.003; cingulum: R = -0.665, P = 0.002) except occipital lobe (R = -0.417, P = 0.076). The hypometabolism to [(18)F]-FDG PET in AD patients also showed negative correlations with regional [(18)F]-APN-1607 binding in some signature areas of AD (temporal lobe: R = -0.530, P = 0.020; parietal lobe: R = -0.637, P = 0.003; occipital lobe: R = -0.567, P = 0.011). In conclusion, our results suggested that [(18)F]-APN-1607 PET sensitively detected tau deposition in AD and that individual tauopathy correlated with impaired cerebral glucose metabolism and cognitive function.
format Online
Article
Text
id pubmed-7338611
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73386112020-07-20 Associations of [(18)F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism Lu, Jiaying Bao, Weiqi Li, Ming Li, Ling Zhang, Zhengwei Alberts, Ian Brendel, Matthias Cumming, Paul Lu, Huimeng Xiao, Zhenxu Zuo, Chuantao Guan, Yihui Zhao, Qianhua Rominger, Axel Front Neurosci Neuroscience Molecular imaging of tauopathies is complicated by the differing specificities and off-target binding properties of available radioligands for positron emission tomography (PET). [(18)F]-APN-1607 ([(18)F]-PM-PBB3) is a newly developed PET tracer with promising properties for tau imaging. We aimed to characterize the cerebral binding of [(18)F]-APN-1607 in Alzheimer’s disease (AD) patients compared to normal control (NC) subjects. Therefore, we obtained static late frame PET recordings with [(18)F]-APN-1607 and [(18)F]-FDG in patients with a clinical diagnosis of AD group, along with an age-matched NC group ([(18)F]-APN-1607 only). Using statistical parametric mapping (SPM) and volume of interest (VOI) analyses of the reference region normalized standardized uptake value ratio maps, we then tested for group differences and relationships between both PET biomarkers, as well as their associations with clinical general cognition. In the AD group, [(18)F]-APN-1607 binding was elevated in widespread cortical regions (P < 0.001 for VOI analysis, familywise error-corrected P < 0.01 for SPM analysis). The regional uptake in AD patients correlated negatively with Mini-Mental State Examination score (frontal lobe: R = -0.632, P = 0.004; temporal lobe: R = -0.593, P = 0.008; parietal lobe: R = -0.552, P = 0.014; insula: R = -0.650, P = 0.003; cingulum: R = -0.665, P = 0.002) except occipital lobe (R = -0.417, P = 0.076). The hypometabolism to [(18)F]-FDG PET in AD patients also showed negative correlations with regional [(18)F]-APN-1607 binding in some signature areas of AD (temporal lobe: R = -0.530, P = 0.020; parietal lobe: R = -0.637, P = 0.003; occipital lobe: R = -0.567, P = 0.011). In conclusion, our results suggested that [(18)F]-APN-1607 PET sensitively detected tau deposition in AD and that individual tauopathy correlated with impaired cerebral glucose metabolism and cognitive function. Frontiers Media S.A. 2020-06-30 /pmc/articles/PMC7338611/ /pubmed/32694971 http://dx.doi.org/10.3389/fnins.2020.00604 Text en Copyright © 2020 Lu, Bao, Li, Li, Zhang, Alberts, Brendel, Cumming, Lu, Xiao, Zuo, Guan, Zhao and Rominger. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Lu, Jiaying
Bao, Weiqi
Li, Ming
Li, Ling
Zhang, Zhengwei
Alberts, Ian
Brendel, Matthias
Cumming, Paul
Lu, Huimeng
Xiao, Zhenxu
Zuo, Chuantao
Guan, Yihui
Zhao, Qianhua
Rominger, Axel
Associations of [(18)F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism
title Associations of [(18)F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism
title_full Associations of [(18)F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism
title_fullStr Associations of [(18)F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism
title_full_unstemmed Associations of [(18)F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism
title_short Associations of [(18)F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism
title_sort associations of [(18)f]-apn-1607 tau pet binding in the brain of alzheimer’s disease patients with cognition and glucose metabolism
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338611/
https://www.ncbi.nlm.nih.gov/pubmed/32694971
http://dx.doi.org/10.3389/fnins.2020.00604
work_keys_str_mv AT lujiaying associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT baoweiqi associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT liming associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT liling associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT zhangzhengwei associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT albertsian associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT brendelmatthias associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT cummingpaul associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT luhuimeng associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT xiaozhenxu associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT zuochuantao associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT guanyihui associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT zhaoqianhua associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism
AT romingeraxel associationsof18fapn1607taupetbindinginthebrainofalzheimersdiseasepatientswithcognitionandglucosemetabolism